On November 6, 2019 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) reported that it will provide an update on its preclinical pipeline at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2019 Congress in National Harbor, Maryland, November 6-10, 2019 (Press release, Innate Pharma, NOV 6, 2019, View Source [SID1234550398]). Highlights will include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In vivo data on anti-CD39 IPH5201 supporting the rationale for assessing combination with PD-1/PD-L1 checkpoint inhibitors
Preclinical results of anti-CD73 IPH5301 targeting the adenosine immunosuppressive pathway
New generation trifunctional NK cell engagers (NKCEs), supporting its clinical development in immunotherapy
Innate will also present in vitro data on IPH5401, demonstrating that the molecule has the potential to block activation and migration of human neutrophils, a major mechanism to allow for the reactivation of effector cells. The Company believes this data supports its ongoing multi-center, open label, dose-escalation and dose expansion Phase I clinical trial (STELLAR-001), evaluating the safety and efficacy of IPH5401 in combination with durvalumab (anti-PD-L1) in patients with advanced solid tumors.

Eric Vivier, Chief Scientific Officer of Innate Pharma, will also give a presentation on harnessing innate imnunity in cancer, as part of the faculty session dedicated to NK cells.

"We are pleased to present data at SITC (Free SITC Whitepaper) 2019 on several of our preclinical and clinical assets, notably three antibodies targeting the tumor microenvironment, as well as on our new NKCEs technology," commented Eric Vivier, Chief Scientific Officer of Innate Pharma. "These data support the science and innovative technologies our scientists continue to develop, helping to further advance our multi-target strategy in immuno-oncology."

Oral presentation:

– Concurrent Session 312: NK Cells: From Basic Science to Clinical Application "Basic Science" presented by Eric Vivier, DVM, PhD, Innate Pharma
Saturday, November 9 | 5:15 pm

Poster presentations:

– IPH5301, a CD73 blocking antibody targeting the adenosine immunosuppressive pathway for cancer immunotherapy, Poster P323
Friday November 8 | 12:30 – 2 pm & 6:30 – 8 pm

– IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, unleashes immune responses in combination with cancer therapies, Poster P488
Saturday November 9 | 12:35 – 2:05 pm & 7 – 8:30 pm

– IPH5401 anti-human C5aR antibody targets suppressive myeloid cells in the TME, Poster P268
Saturday November 9 | 12:35 – 2:05 pm & 7 – 8:30 pm

– Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity, Poster P776
Saturday November 9 | 12:35 – 2:05 pm & 7 – 8:30 pm